2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Carcinoma, Transitional Cell
29
Carcinoma, Non-Small-Cell Lung
29
Urinary Bladder Neoplasms
26
Neoplasms
22
Carcinoma, Renal Cell
22
Carcinoma, Merkel Cell
21
Neoplasm Metastasis
18
Colorectal Neoplasms
16
Breast Neoplasms
16
Squamous Cell Carcinoma of Head and Neck
15
Ovarian Neoplasms
14
Triple Negative Breast Neoplasms
11
Pancreatic Neoplasms
9
Melanoma
9
Head and Neck Neoplasms
8
Stomach Neoplasms
7
Recurrence
6
Carcinoma, Hepatocellular
6
Ureteral Neoplasms
5
Small Cell Lung Carcinoma
5
Prostatic Neoplasms
5
Urethral Neoplasms
4
Sarcoma
4
Neuroendocrine Tumors
4
Leukemia, Myeloid, Acute
4
Glioblastoma
4
Carcinoma, Squamous Cell
4
Uterine Cervical Neoplasms
3
Turcot syndrome
3
Skin Neoplasms
3
Interventions
Cyclophosphamide
193
fludarabine phosphate
123
Peripheral Blood Stem Cell Transplantation
107
Etoposide
106
Mycophenolic Acid
95
Filgrastim
92
Doxorubicin
85
Whole-Body Irradiation
84
Tacrolimus
81
Brentuximab Vedotin
80
Melphalan
78
Busulfan
75
Radiotherapy
74
fludarabine
68
Cyclosporine
67
Vinblastine
65
Rituximab
60
Dacarbazine
56
Granulocyte Colony-Stimulating Factor
53
Gemcitabine
52
Antilymphocyte Serum
51
Bleomycin
50
Nivolumab
47
Methotrexate
47
Vincristine
46
Prednisone
45
Cytarabine
44
pembrolizumab
36
Carmustine
36
Bendamustine Hydrochloride
32
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Hodgkin Disease
×
avelumab
×
Clear all
NCT03617666
2023-12-12
AVENuE
University College, London
Phase 2
Unknown
49 enrolled
NCT02603419
2020-04-24
JAVELIN HODGKINS
Pfizer
Phase 1
Terminated
34 enrolled
43 charts